---
title: "Hemab Therapeutics Holdings, Inc. (COAG.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/COAG.US.md"
symbol: "COAG.US"
name: "Hemab Therapeutics Holdings, Inc."
datetime: "2026-05-01T13:26:46.130Z"
locales:
  - [en](https://longbridge.com/en/quote/COAG.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/COAG.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/COAG.US.md)
---

# Hemab Therapeutics Holdings, Inc. (COAG.US)

## Company Overview

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets.

| Item | Detail |
|------|--------|
| Exchange | US Market |
| Website | [www.hemab.com](https://www.hemab.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/COAG.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/COAG.US/norm.md)
- [Related News](https://longbridge.com/en/quote/COAG.US/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**